Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX(R) (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy

WAKIX is the first and only non-scheduled treatment approved for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Harmony Bioscienc... Biopharmaceuticals, FDA Harmony Biosciences, WAKIX, pitolisant, cataplexy, narcolepsy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news